China (Mainland)
ASP-2215 Gilteritinib hemifumarate CAS NO.1254053-84-3
- Min.Order: 1 Gram
- Payment Terms: T/T
- Product Details
Keywords
- supplier Custom synthesis
- manufacturer low price
- high quality Acute myeloid leukemia
Quick Details
- ProName: ASP-2215 Gilteritinib hemifumarate
- CasNo: 1254053-84-3
- Appearance: white powder
- Application: Use for API ,parmaceutical intermediat...
- DeliveryTime: In stock
- PackAge: brown vial + Aluminum foil bag +box(Pa...
- Port: jinan
- ProductionCapacity: 1 Gram/Day
- Purity: 95% min
- Storage: Store in dry/sealed/low temperature
- Transportation: by sea by air
- LimitNum: 1 Gram
Superiority
Known for its best quality and competitve price, this chemicals we offered is widely appreciated by our customers.
1) All Purity≥95%
2) We are manufacturer and can provide high quality products with factory price.
2, Fast and safe delivery
2) Secure and discreet shipment.Various transportation methods for your choice.
Details
Our Company
Shandong Bolode Bio-Technology Co., Ltd is a professional company which engaged in the R&D and manufacture of Pharmaceuticals intermediates and Chemical Raw materials. The company is located in Jinan, the capital of Shandong Province. With the advanced equipment, quality management and many years producing experience, The company has completed quality ass urance system and strong research and innovation ability.
Purity : 95%+ min
Supply COA , HPLC ,HNMR ,MASS
Direct manufacturers with high quality and best price !
Xospata belongs to the second generation of FLT3 inhibitors, which has inhibitory effects on two different mutations in FLT3 transmembrane region internal tandem repeat (ITD) and FLT3 tyrosine kinase domain (TKD). Xospata (Gilteritinib) is a drug that inhibits cell growth by blocking FLT3 and other proteins on cancer cells. This drug can treat adult patients whose leukemia cells have FLT3 gene mutations and whose AML has not been effective in previous treatments or have relapsed.
The drug has been approved for marketing in Japan and the United States in 2018 for the treatment of adult patients with relapsed or refractory FLT3 mutant acute myeloid leukemia. It is the first FDA-approved treatment for relapsed refractory acute myeloid leukemia. FLT3 inhibitor.On April 10, 2020, Astellas announced that it had submitted a new drug listing application (NDA) for Xospata (gilteritinib) giritinib, which was accepted by the National Medical Products Administration (NMPA) for the treatment of FLT3 mutation positive (FLT3mut+) Of adult patients with relapsed or refractory (treatment resistant) acute myeloid leukemia (AML)